The hinge-engineered IgG1-IgG3 hybrid subclass IgGh


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
27 Apr 2024
Historique:
received: 30 06 2023
accepted: 15 04 2024
medline: 28 4 2024
pubmed: 28 4 2024
entrez: 27 4 2024
Statut: epublish

Résumé

Streptococcus pyogenes can cause invasive disease with high mortality despite adequate antibiotic treatments. To address this unmet need, we have previously generated an opsonic IgG1 monoclonal antibody, Ab25, targeting the bacterial M protein. Here, we engineer the IgG2-4 subclasses of Ab25. Despite having reduced binding, the IgG3 version promotes stronger phagocytosis of bacteria. Using atomic simulations, we show that IgG3's Fc tail has extensive movement in 3D space due to its extended hinge region, possibly facilitating interactions with immune cells. We replaced the hinge of IgG1 with four different IgG3-hinge segment subclasses, IgGh

Identifiants

pubmed: 38678029
doi: 10.1038/s41467-024-47928-8
pii: 10.1038/s41467-024-47928-8
doi:

Substances chimiques

Immunoglobulin G 0
Antibodies, Viral 0
Immunoglobulin Fc Fragments 0
Antibodies, Monoclonal 0
Antibodies, Bacterial 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

3600

Informations de copyright

© 2024. The Author(s).

Références

Vidarsson, G., Dekkers, G. & Rispens, T. IgG subclasses and allotypes: From structure to effector functions. Frontiers in Immunology. 5, 1–17 (2014).
doi: 10.3389/fimmu.2014.00520
Roco, J. A. et al. Class-switch recombination occurs infrequently in germinal centers. Immunity. 51, 337–350 (2019).
pubmed: 31375460 pmcid: 6914312 doi: 10.1016/j.immuni.2019.07.001
Oi, V. T. et al. Correlation between segmental flexibility and effector function of antibodies. Nature. 307, 136–140 (1984).
pubmed: 6690993 doi: 10.1038/307136a0
Torres, M. & Casadevall, A. The immunoglobulin constant region contributes to affinity and specificity. Trends in Immunology. 29, 91–97 (2008).
pubmed: 18191616 doi: 10.1016/j.it.2007.11.004
Janda, A., Bowen, A., Greenspan, N. S. & Casadevall, A. Ig constant region effects on variable region structure and function. Frontiers in Microbiology. 7, 1–10 (2016).
doi: 10.3389/fmicb.2016.00022
Janda, A., Eryilmaz, E., Nakouzi, A., Cowburn, D. & Casadevall, A. Variable region identical immunoglobulins differing in isotype express different paratopes. Journal of Biological Chemistry. 287, 35409–35417 (2012).
pubmed: 22930758 pmcid: 3471687 doi: 10.1074/jbc.M112.404483
Hovenden, M. et al. IgG subclass and heavy chain domains contribute to binding and protection by mAbs to the Poly γ-D-glutamic acid capsular antigen of bacillus anthracis. PLoS Pathogens. 9, 1–11 (2013).
doi: 10.1371/journal.ppat.1003306
Roux, K. H., Strelets, L. & Michaelsen, T. E. Flexibility of human IgG subclasses. J Immunol. 159, 3372–3382 (1997).
pubmed: 9317136 doi: 10.4049/jimmunol.159.7.3372
Bindon, C. I., Hale, G., Brüggemann, M. & Waldmann, H. Human monoclonal IgG isotypes differ in complement activating function at the level of C4 as well as C1q. J. Exp. Med. 168, 127–142 (1988).
pubmed: 3260935 doi: 10.1084/jem.168.1.127
Bruhns, P. et al. Specificity and affinity of human Fcγ receptors and their polymorphic variants for human IgG subclasses. Blood. 113, 3716–3725 (2009).
pubmed: 19018092 doi: 10.1182/blood-2008-09-179754
Bahnan, W. et al. A human monoclonal antibody bivalently binding two different epitopes in streptococcal M protein protects against infection. EMBO Mol. Med. 14, 1–21 (2022).
Mcnamara, C. et al. Streptococcus M1 Are Required for Virulence. Science. 319, 1405–1408 (2008).
pubmed: 18323455 pmcid: 2288698 doi: 10.1126/science.1154470
Nordenfelt, P. et al. Antibody orientation at bacterial surfaces is related to invasive infection. J. Exp. Med. 209, 2367–2381 (2012).
pubmed: 23230002 pmcid: 3526361 doi: 10.1084/jem.20120325
Khakzad, H. et al. Structural determination of Streptococcus pyogenes M1 protein interactions with human immunoglobulin G using integrative structural biology. PLoS Computational Biology. 17, 1–19 (2021).
doi: 10.1371/journal.pcbi.1008169
Wrighton, S., Ahnlide, KumraV., Andre, O., Bahnan, W. & Nordenfelt, P. Group A streptococci induce stronger M protein-fibronectin interaction when specific human antibodies are bound. Frontiers in Microbiology. 14, 1069789 (2023).
pubmed: 36778879 pmcid: 9909010 doi: 10.3389/fmicb.2023.1069789
Carlsson, F., Sandin, C. & Lindahl, G. Human fibrinogen bound to Streptococcus pyogenes M protein inhibits complement deposition via the classical pathway. Molecular Microbiology. 56, 28–39 (2005).
pubmed: 15773976 doi: 10.1111/j.1365-2958.2005.04527.x
Dale, J. B. & Walker, M. J. Update on group A streptococcal vaccine development. Curr Opin Infect Dis. 33, 244–250 (2020).
pubmed: 32304470 pmcid: 7326309 doi: 10.1097/QCO.0000000000000644
Happonen, L. et al. A quantitative Streptococcus pyogenes–human protein–protein interaction map reveals localization of opsonizing antibodies. Nat Commun 10, 2727 (2019).
pubmed: 31227708 pmcid: 6588558 doi: 10.1038/s41467-019-10583-5
Nilson, B. H. et al. Structure and stability of protein H and the M1 protein from Streptococcus pyogenes. Implications for other surface proteins of gram-positive bacteria. Biochemistry. 34, 13688–13698 (1995).
pubmed: 7577960 doi: 10.1021/bi00041a051
Ackerman, M. E. et al. A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples. Journal of immunological methods. 366, 8–19 (2011).
pubmed: 21192942 doi: 10.1016/j.jim.2010.12.016
Karsten, C. B. et al. A versatile high-throughput assay to characterize antibody-mediated neutrophil phagocytosis. Journal of immunological methods. 471, 46–56 (2019).
pubmed: 31132351 pmcid: 6620195 doi: 10.1016/j.jim.2019.05.006
Mackin, S. R. et al. Fc-γR-dependent antibody effector functions are required for vaccine-mediated protection against antigen-shifted variants of SARS-CoV-2. Nature microbiology. 8, 569–580 (2023).
pubmed: 37012355 pmcid: 10797606 doi: 10.1038/s41564-023-01359-1
de Neergaard, T., Sundwall, M., Wrighton, S. & Nordenfelt, P. High-sensitivity assessment of phagocytosis by persistent association-based normalization. J Immunol. 206, 214–224 (2021).
pubmed: 33268484 doi: 10.4049/jimmunol.2000032
Varshney, A. K. et al. A natural human monoclonal antibody targeting Staphylococcus Protein A protects against Staphylococcus aureus bacteremia. PLoS ONE. 13, 1–22 (2018).
doi: 10.1371/journal.pone.0190537
Stapleton, N. M. et al. Competition for FcRn-mediated transport gives rise to short half-life of human IgG3 and offers therapeutic potential. Nat Commun. 2, 599 (2011).
pubmed: 22186895 doi: 10.1038/ncomms1608
Chu, T. H. et al. Hinge length contributes to the phagocytic activity of HIV-specific IgG1 and IgG3 antibodies. PLoS Pathogens. 16, 1–25 (2020).
doi: 10.1371/journal.ppat.1008083
Woof, J. M. & Burton, D. R. Human antibody-Fc receptor interactions illuminated by crystal structures. Nature Reviews Immunology. 4, 89–99 (2004).
pubmed: 15040582 doi: 10.1038/nri1266
Radaev, S. & Sun, P. Recognition of immunoglobulins by Fcγ receptors. Molecular Immunology. 38, 1073–1078 (2002).
pubmed: 11955599 doi: 10.1016/S0161-5890(02)00036-6
Toledo, A. G. et al. Pathogen-driven degradation of endogenous and therapeutic antibodies during streptococcal infections. Nat Commun. 14, 6693 (2023).
pubmed: 37872209 pmcid: 10593946 doi: 10.1038/s41467-023-42572-0
Karlsson, C. A. Q. et al. Streptococcus pyogenes Infection and the Human Proteome with a Special Focus on the Immunoglobulin G-cleaving Enzyme IdeS. Mol Cell Proteomics. 17, 1097–1111 (2018).
pubmed: 29511047 pmcid: 5986240 doi: 10.1074/mcp.RA117.000525
Crowley, A. R. et al. Evidence of variable human Fcγ receptor-Fc affinities across differentially-complexed IgG. mAbs 15, 2231128 (2023).
pubmed: 37405954 pmcid: 10324447 doi: 10.1080/19420862.2023.2231128
Sanderson-Smith, M., De Oliveira, D. M. P., Guglielmini, J., McMillan, D. J. & Vu, T. A systematic and functional classification of streptococcus pyogenes that serves as a new tool for molecular typing and vaccine development. J Infect Dis 210, 1325–1338 (2014).
pubmed: 24799598 pmcid: 6083926 doi: 10.1093/infdis/jiu260
Bartsch et al. Omicron variant Spike-specific antibody binding and Fc activity is preserved in recipients of mRNA or inactivated COVID-19 vaccines. Sci. Transl. Med. 14, eabn9243 (2022).
pubmed: 35289637 doi: 10.1126/scitranslmed.abn9243
Ullah, I. et al. The Fc-effector function of COVID-19 convalescent plasma contributes to SARS-CoV-2 treatment efficacy in mice. Cell Rep. Med. 4, 100893 (2023).
pubmed: 36584683 doi: 10.1016/j.xcrm.2022.100893
Kaplonek, P. et al. mRNA-1273 vaccine-induced antibodies maintain Fc effector functions across SARS-CoV-2 variants of concern. Immunity. 55, 355–365 (2022).
pubmed: 35090580 pmcid: 8733218 doi: 10.1016/j.immuni.2022.01.001
Beaudoin-Bussières, G. et al. A Fc-enhanced NTD-binding non-neutralizing antibody delays virus spread and synergizes with a nAb to protect mice from lethal SARS-CoV-2 infection. Cell Rep. 38, 110368 (2022).
pubmed: 35123652 pmcid: 8786652 doi: 10.1016/j.celrep.2022.110368
Izadi, A. et al. Subclass-switched anti-spike IgG3 oligoclonal cocktails strongly enhance Fc-mediated opsonization. Proc. Natl. Acad. Sci. USA. 120, e2217590120 (2023).
pubmed: 37011197 pmcid: 10104557 doi: 10.1073/pnas.2217590120
Bahnan, W. et al. Spike-dependent opsonization indicates both dose-dependent inhibition of phagocytosis and that non-neutralizing antibodies can confer protection to SARS-CoV-2. Front. Immunol. 12, 808932 (2022).
pubmed: 35095897 pmcid: 8796240 doi: 10.3389/fimmu.2021.808932
Kaplon, H., Crescioli, S., Chenoweth, A., Visweswaraiah, J. & Reichert, J. M. Antibodies to watch in 2023. mAbs. 15, 2297450 (2023).
doi: 10.1080/19420862.2022.2153410
Hammitt L. L., et al Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants. N. Engl. J. Med. 386, 837-846 (2022).
Brinda, E. et al. Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1. N Engl J Med. 379, 645–654 (2018).
doi: 10.1056/NEJMoa1711460
Chen, P. et al. SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with 703 Covid-19. N. Engl. J. Med. 384, 229–237 (2021).
pubmed: 33113295 doi: 10.1056/NEJMoa2029849
Kallolimath, S. et al. Highly active engineered IgG3 antibodies against SARS-CoV-2. Proc. Natl. Acad. Sci. USA. 118, e2107249118 (2021).
pubmed: 34599091 pmcid: 8545452 doi: 10.1073/pnas.2107249118
Giuntini, S., Reason, D. C. & Granoff, D. M. Combined roles of human IgG subclass, alternative complement pathway activation, and epitope density in the bactericidal activity of antibodies to meningococcal factor H binding protein. Infection and Immunity. 80, 187–194 (2012).
pubmed: 22064712 pmcid: 3255668 doi: 10.1128/IAI.05956-11
Chu, T. H., Patz, E. F. & Ackerman, M. E. Coming together at the hinges: Therapeutic prospects of IgG3. MAbs. 13, 1882028 (2021).
pubmed: 33602056 pmcid: 7899677 doi: 10.1080/19420862.2021.1882028
Saito, S., Namisaki, H., Hiraishi, K., Takahashi, N. & Iida, S. A stable engineered human IgG3 antibody with decreased aggregation during antibody expression and low pH stress. Protein Sci. 28, 900–909 (2019).
pubmed: 30834577 pmcid: 6459999 doi: 10.1002/pro.3598
Foss, S. et al. Potent TRIM21 and complement-dependent intracellular antiviral immunity requires the IgG3 hinge. Sci Immunol. 7, eabj1640 (2022).
pubmed: 35486676 pmcid: 7614286 doi: 10.1126/sciimmunol.abj1640
Bazin, R. et al. Use of hu-IgG-SCID mice to evaluate the in vivo stability of human monoclonal IgG antibodies. J Immunol Methods. 172, 209–217 (1994).
pubmed: 7518484 doi: 10.1016/0022-1759(94)90108-2
Brinkhaus, M. et al. The Fab region of IgG impairs the internalization pathway of FcRn upon Fc engagement. Nature communications 13, 6073 (2022).
pubmed: 36241613 pmcid: 9568614 doi: 10.1038/s41467-022-33764-1
Dekkers, G. et al. Affinity of human IgG subclasses to mouse Fc gamma receptors. mAbs. 9, 767–773 (2017).
pubmed: 28463043 pmcid: 5524164 doi: 10.1080/19420862.2017.1323159
Bruhns, Pierre Properties of mouse and human IgG receptors and their contribution to disease models. Blood 119, 5640–5649 (2012).
pubmed: 22535666 doi: 10.1182/blood-2012-01-380121
Overdijk, M. B. et al. Crosstalk between human IgG isotypes and murine effector cells. J Immunol 189, 3430–3438 (2012).
pubmed: 22956577 doi: 10.4049/jimmunol.1200356
Steplewski, Z. et al. Biological activity of human-mouse IgG1, IgG2, IgG3, and IgG4 chimeric monoclonal antibodies with antitumor specificity. Proc Natl Acad Sci USA 85, 4852–4856 (1988).
pubmed: 3387441 pmcid: 280534 doi: 10.1073/pnas.85.13.4852
Dodev, T. S. et al. A tool kit for rapid cloning and expression of recombinant antibodies. Sci Rep. 4, 5885 (2014).
pubmed: 25073855 pmcid: 4115235 doi: 10.1038/srep05885
Medina, E., Goldmann, O., Rohde, M., Lengeling, A. & Chhatwal, G. S. Genetic control of susceptibility to group A streptococcal infection in mice. J Infect Dis. 184, 846–852 (2001).
pubmed: 11550125 doi: 10.1086/323292
Mirdita, M. et al. ColabFold - Making protein folding accessible to all. Nature Methods. 19, 679–682 (2022).
pubmed: 35637307 pmcid: 9184281 doi: 10.1038/s41592-022-01488-1
Jumper, J. et al. Highly accurate protein structure prediction with AlphaFold. Nature. 596, 583–589 (2021).
pubmed: 34265844 pmcid: 8371605 doi: 10.1038/s41586-021-03819-2
Steinegger, M. & Söding, J. MMseqs2 enables sensitive protein sequence searching for the analysis of massive data sets. Nature Biotechnology. 35, 1026–1028 (2017).
pubmed: 29035372 doi: 10.1038/nbt.3988
Leman, J. K. et al. Macromolecular modeling and design in Rosetta: recent methods and frameworks. Nature Methods. 17, 665–680 (2020).
pubmed: 32483333 doi: 10.1038/s41592-020-0848-2
Hauri, S. et al. Rapid determination of quaternary protein structures in complex biological samples. Nat Commun. 10, 1–10 (2019).
doi: 10.1038/s41467-018-07986-1
Karami, Y. et al. DaReUS-Loop: a web server to model multiple loops in homology models. Nucleic Acids Research. 47, W423–W428 (2019).
pubmed: 31114872 pmcid: 6602439 doi: 10.1093/nar/gkz403
Karami, Y., Guyon, F., de Vries, S. & Tufféry, P. DaReUS-Loop: accurate loop modeling using fragments from remote or unrelated proteins. Scientific Reports. 8, 1–12 (2018).
doi: 10.1038/s41598-018-32079-w
van der Spoel, D. et al. GROMACS: Fast, flexible, and free. Journal of Computational Chemistry. 26, 1701–1718 (2005).
pubmed: 16211538 doi: 10.1002/jcc.20291
Williams C. J., et al MolProbity: More and better reference data for improved all-atom structure validation. Protein Science. 27, 293–315 (2018)
Loncharich, R. J., Brooks, B. R. & Pastor, R. W. Langevin dynamics of peptides: The frictional dependence of isomerization rates of N‐acetylalanyl‐N′‐methylamide. Biopolymers. 32, 523–535 (1992).
pubmed: 1515543 doi: 10.1002/bip.360320508
York, D. M., Darden, T. A. & Pedersen, L. G. The effect of long-range electrostatic interactions in simulations of macromolecular crystals: A comparison of the Ewald and truncated list methods. The Journal of Chemical Physics. 99, 8345–8348 (1993).
doi: 10.1063/1.465608
McDonald, I. K. & Thornton, J. M. Satisfying Hydrogen Bonding Potential in Proteins. JMB 238, 777–793 (1994).
doi: 10.1006/jmbi.1994.1334
Humphrey, W., Dalke, A. & Schulten, K. VMD: visual molecular dynamics. J Mol Graph 14, 33–38 (1996).
pubmed: 8744570 doi: 10.1016/0263-7855(96)00018-5
Schymkowitz, J. et al. The FoldX web server: an online force field. Nucleic Acids Res. 33, 382–388 (2005).
doi: 10.1093/nar/gki387
Incardona, E. D. N. A. et al. O. EDNA: a framework for plugin-based applications applied to X-ray experiment online data analysis. J. Synchrotron Radiat. 16, 872–879 (2009).
pubmed: 19844027 doi: 10.1107/S0909049509036681
Adams, P. et al. PHENIX: A comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D. 66, 213–221 (2010).
pubmed: 20124702 pmcid: 2815670 doi: 10.1107/S0907444909052925
Emsley, P., Lohkamp, B., Scott, W. & Cowtan, K. Features and development of coot. Acta Cryst D. 66, 486–501 (2010).
doi: 10.1107/S0907444910007493

Auteurs

Arman Izadi (A)

Department of Clinical Sciences Lund, Infection Medicine, Faculty of Medicine, Lund University, Lund, Sweden.

Yasaman Karami (Y)

Université de Lorraine, CNRS, Inria, LORIA, F-54000, Nancy, France.
Institut Pasteur, Université Paris cite, CNRS UMR3528, Structural Bioinformatics Unit, Department of Structural Biology and Chemistry, F-75015, Paris, France.

Eleni Bratanis (E)

Department of Clinical Sciences Lund, Infection Medicine, Faculty of Medicine, Lund University, Lund, Sweden.

Sebastian Wrighton (S)

Department of Clinical Sciences Lund, Infection Medicine, Faculty of Medicine, Lund University, Lund, Sweden.

Hamed Khakzad (H)

Université de Lorraine, CNRS, Inria, LORIA, F-54000, Nancy, France.

Maria Nyblom (M)

Department of Biology & Lund Protein Production Platform (LP3), Lund University, Lund, Sweden.

Berit Olofsson (B)

Department of Clinical Sciences Lund, Infection Medicine, Faculty of Medicine, Lund University, Lund, Sweden.

Lotta Happonen (L)

Department of Clinical Sciences Lund, Infection Medicine, Faculty of Medicine, Lund University, Lund, Sweden.

Di Tang (D)

Department of Clinical Sciences Lund, Infection Medicine, Faculty of Medicine, Lund University, Lund, Sweden.

Martin Sundwall (M)

Department of Clinical Sciences Lund, Infection Medicine, Faculty of Medicine, Lund University, Lund, Sweden.

Magdalena Godzwon (M)

Department of Immunotechnology and SciLifeLab Drug Discovery and Development Platform, Lund University, Lund, Sweden.

Yashuan Chao (Y)

Department of Clinical Sciences Lund, Infection Medicine, Faculty of Medicine, Lund University, Lund, Sweden.

Alejandro Gomez Toledo (AG)

Department of Clinical Sciences Lund, Infection Medicine, Faculty of Medicine, Lund University, Lund, Sweden.

Tobias Schmidt (T)

Department of Clinical Sciences Lund, Division of Pediatrics, Faculty of Medicine, Lund University, Lund, Sweden.

Mats Ohlin (M)

Department of Immunotechnology and SciLifeLab Drug Discovery and Development Platform, Lund University, Lund, Sweden.

Michael Nilges (M)

Institut Pasteur, Université Paris cite, CNRS UMR3528, Structural Bioinformatics Unit, Department of Structural Biology and Chemistry, F-75015, Paris, France.

Johan Malmström (J)

Department of Clinical Sciences Lund, Infection Medicine, Faculty of Medicine, Lund University, Lund, Sweden.

Wael Bahnan (W)

Department of Clinical Sciences Lund, Infection Medicine, Faculty of Medicine, Lund University, Lund, Sweden.

Oonagh Shannon (O)

Department of Clinical Sciences Lund, Infection Medicine, Faculty of Medicine, Lund University, Lund, Sweden.
Section for Oral Biology and Pathology, Faculty of Odontology, Malmö University, Malmö, Sweden.

Lars Malmström (L)

Department of Clinical Sciences Lund, Infection Medicine, Faculty of Medicine, Lund University, Lund, Sweden.

Pontus Nordenfelt (P)

Department of Clinical Sciences Lund, Infection Medicine, Faculty of Medicine, Lund University, Lund, Sweden. pontus.nordenfelt@med.lu.se.
Department of Laboratory Medicine, Clinical Microbiology, Skåne University Hospital Lund, Lund University, Lund, Sweden. pontus.nordenfelt@med.lu.se.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH